

2007/2008 Lung Health Funding / Agreements

RESEARCHER	AWARD AMOUNT	AGENCY	AWARD TYPE	TITLE
Road, Jeremy	\$13,375.00	AstraZeneca AB	Agreement	D5892C00015: A 12 week, double-blind, randomised, parallel group, multi-centre, study to evaluate efficacy and safety of budesonide/formoterol (Symbicort Turbuhaler) 320/9 ug one inhalation twice daily on top of tiotropium (Spiriva) 18ug on
Fitzgerald, Mark	\$19,800.30	Boehringer Ingelheim (Canada) Ltd.	Agreement	BI1744CL - 1222.6: Randomized, Double-Blind, Placebo-Controlled, Parallel Group study to Assess the Efficacy (Bronchodilation) and safety of 4 weeks of once daily treatment of orally inhaled BI 1744 CL (2ug, 5ug, 10ug, 20ug) delivered by Ri
Road, Jeremy	\$11,700.00	Boehringer Ingelheim (Canada) Ltd.	Agreement	Effect of Inhalation of a Free combination of Tiotropium once Daily 18 mcg and Salmeterol Twice Daily 50 mcg versus a Fixed Combination of Fluticasone and Salmeterol Twice Daily (500/50 mcg) on Static Lung Volumes and Exercise Tolerance in O
Turvey, Stuart	\$15,000.00	British Columbia Innovation Council	Agreement	Identification of TLR5 Antagonists
Abu-Laban, Riyad	\$330.00	Canadian Institutes of Health Research (CIHR)	Agreement	Study of anti-inflammatory treatment in asthma relapse: (AIR study)
Road, Jeremy	\$12,285.17	Forest Laboratories Inc.	Agreement	LAS-MD-CL26: A Randomized, double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Effect of Inhaled Acridinium Bromide ((LAS34273) 200 ug on Exercise Endurance and Lung Hyperinflation in Patients with Moderat
Fitzgerald, Mark	\$5,808.42	Genentech Inc.	Agreement	Q4160g:A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lyphilized and Aged Liquid Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adul
Fitzgerald, Mark	\$54,566.46	GlaxoSmithKline (Canada) Inc.	Agreement	ECLIPSE: A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These with Forced Expiratory Volume in 1 Second (FEV) for their ability to Measure and Predict COPD Severity and its progression Over Tim
Fitzgerald, Mark	\$100,000.00	GlaxoSmithKline (Canada) Inc.	Agreement	The Development of Asthma Education Programs Through a Novel Chronic Disease Management Model: PRIISM
Van Eeden, Stephanus	\$42,000.00	GlaxoSmithKline (Canada) Inc.	Agreement	PRIISME PROGRAM
Abboud, Raja	\$45,000.00	Hoffmann-La Roche Ltd. (Canada)	Agreement	PATIENT REIMBURSEMENT ACCOUNT FOR STUDY na17598
Abboud, Raja	\$155,085.77	Hoffmann-La Roche Ltd. (Canada)	Agreement	Protocol: NA17598D, A multicenter, double-blind, placebo-controlled randomized trial of the efficacy safety and tolerability of 12 months of once daily treatment with 5mg of RO3300074 in patients with symptomatic emphysema secondary to alphy
Fitzgerald, Mark	\$6,900.00	Hoffmann-La Roche Ltd.	Agreement	NA20030A: Roche Integrin Antagonist Follow-up for Undetected PML

2007/2008 Lung Health Funding / Agreements

RESEARCHER	AWARD AMOUNT	AGENCY	AWARD TYPE	TITLE
Khalil, Nasreen	\$45,246.37	InterMune Inc.	Agreement	PIPF-004: A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three Arm Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Churg, Andrew	\$93,600.00	National Institutes of Health	Agreement	Dynamic strengths of leukocyte adhesion bonds
Hogg, James	\$91,800.00	National Institutes of Health	Agreement	IICT: Alveolar and Airway Mechanisms for COPD Project 1 Detection: Lung Imaging and Profiling
Fitzgerald, Mark	\$1,100.00	Novartis Pharmaceuticals Canada Inc.	Agreement	CIGE025ACA02: XCEED Xolair Canadian Evaluation of Effectiveness in Asthmatic Disease: A Post-Registration Evaluation of Long Term Xolair (omalizumab) Therapy on Patient-Relevant Outcomes, Medical Resource Use and Asthma Medication Requirs
Fitzgerald, Mark	\$3,000.00	Novartis Pharmaceuticals Canada Inc.	Agreement	CQAB149B2335S: A 26 Week Treatment, Multicenter, Randomized, Double-Blind, Double Dummy, Placebo-Controlled, Adaptive, Seamless, Parallel-Group Study to Assess the Efficacy, Safety and Tolerability of Two Doses of Indacaterol (selected fro,
Fitzgerald, Mark	\$4,000.00	Novartis Pharmaceuticals Canada Inc.	Agreement	CIGE025A2433: International Registry of Real-World Outcomes for Asthma Patients Treated with Xolair
Road, Jeremy	\$32,760.00	Nycomed Canada Inc.	Agreement	BY217/M2-127 "THE EOS STUDY": Effect of Roflumilast in COPD Patients treated with Salmeterol. A 24 Week, Double-Blind Study with 500 ug Roflumilast Once Daily Versus Placebo
Fitzgerald, Mark	\$34,437.50	Skye Pharma	Agreement	SKY2028-3-002 Double-Blind, Active-Controlled, Parallel Group, Stratified, Multi-Center, 12 Week Study Comparing The Safety and Efficacy of Fluticasone and Formoterol combination (Flutiform 100/10ug twice daily) in a Single Inhaler (SkyePhn
Road, Jeremy	\$2,856.60	Synapse Biomedical Inc.	Agreement	CLIN 20-0009-0005 rev4: Pivotal Study of NeuRx RA/4 Motor-Point Stimulation for Conditioning the Diaphragm of Patients with Amyotropic Lateral Sclerosis (ALS)
Fitzgerald, Mark	\$17,253.60	Topigen Pharmaceuticals Inc.	Agreement	TPI ASM8-204: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Groups, Multicenter Study to Evaluate and Compare the Safety, Tolerability and the Efficacy of Two Dosages of Inhaled TPIASM8 (0.25mg vs 0.5mg) with Placebo i
Road, Jeremy	\$8,070.40	Topigen Pharmaceuticals Inc.	Agreement	TPI1020-203: A Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled, 6-Week Study to Evaluate the Safety, Tolerability and Pharmacodynamic Activity of Inhaled TPI1020 in COPD Patients
Knight, Darryl	\$10,000.00	UBC Industry Liaison Office	Agreement	Novel Method for Treatment of Asthma
Ostrow, David	\$900.30	United Therapeutics Corp.	Agreement	TDE-PH-304: An Open-Label Extension Trial of UT015C in Subjects with Pulmonary Arterial Hypertension
Ostrow, David	\$16,761.95	United Therapeutics Corp.	Agreement	TDE-PH-301: A 16 week, International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C SR Tablets in Combination with an Ednothelin Receptor antagonist and/or a Phosphodiestera